BioXcel Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $250.00K, a 35.14% increase year-over-year.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-03-31 was $258.00K.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $48.00K, a 54.29% decline year-over-year.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $185.00K, a 62.78% decline year-over-year.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $508.00K, a 79.51% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $283.00K, a 80.54% decline from fiscal 2021.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.45M, a 143.14% increase from fiscal 2020.
- BioXcel Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $598.00K, a 2618.18% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2023-12-31 | $508.00K 10-K · filed 2025-03-28 | |
| 2023-06-30 | $250.00K 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $258.00K 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $283.00K 10-K · filed 2024-03-22 | |
| 2022-09-30 | $48.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $185.00K 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $1.45M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $105.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $497.00K 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $852.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $598.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $21.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $271.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $39.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $22.00K 10-K · filed 2021-03-12 | |
| 2019-03-31 | $1.00K 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $7.00K 10-K · filed 2020-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |